CDT Equity Inc. (NASDAQ:CDT) Short Interest Up 25.6% in December

CDT Equity Inc. (NASDAQ:CDT) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 111,333 shares, a growth of 25.6% from the November 30th total of 88,617 shares. Approximately 7.4% of the company’s shares are short sold. Based on an average daily volume of 356,497 shares, the short-interest ratio is currently 0.3 days. Based on an average daily volume of 356,497 shares, the short-interest ratio is currently 0.3 days. Approximately 7.4% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CDT Equity in a report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CDT Equity stock. Apollon Wealth Management LLC purchased a new position in shares of CDT Equity Inc. (NASDAQ:CDT) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 107,454 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned approximately 28.28% of CDT Equity at the end of the most recent reporting period. 3.29% of the stock is currently owned by hedge funds and other institutional investors.

CDT Equity Trading Down 7.7%

Shares of CDT stock opened at $1.31 on Wednesday. The company has a market cap of $2.14 million, a P/E ratio of 0.00 and a beta of 1.78. The firm has a fifty day moving average price of $2.09 and a 200 day moving average price of $8.68. CDT Equity has a 12 month low of $1.30 and a 12 month high of $2,198.40.

CDT Equity (NASDAQ:CDT) last released its quarterly earnings data on Thursday, November 13th. The company reported ($13.16) EPS for the quarter.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.